S-1与聚乙二醇化干扰素α联合治疗晚期肝细胞癌

Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma.

作者信息

Ueshima Kazuomi, Kudo Masatoshi, Nagai Tomoyuki, Tatsumi Chie, Ueda Taisuke, Takahashi Shunsuke, Hatanaka Kinuyo, Kitai Satoshi, Ishikawa Emi, Inoue Tatsuo, Hagiwara Satoru, Minami Yasunori, Chung Hobyung

机构信息

Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan.

出版信息

Oncology. 2008;75 Suppl 1:106-13. doi: 10.1159/000173431. Epub 2008 Dec 17.

DOI:10.1159/000173431

PMID:19092279

Abstract

PURPOSE

There are currently no effective treatments for patients with advanced hepatocellular carcinoma (HCC) with vascular invasion or extrahepatic metastases. We evaluated the efficacy and safety of combination therapy with S-1 and pegylated interferon (PEG-IFN)-alpha for advanced HCC.

METHODS

A total of 22 patients received combination therapy with S-1 and PEG-IFN. One cycle of the combination therapy consists of oral S-1 (80 mg/m(2)) administration and subcutaneous PEG-IFN injection (PEG-IFN-alpha-2a 90 microg weekly or PEG-IFN-alpha-2b 50 microg weekly) for 4 weeks with 1- to 2-week intervals.

RESULTS

One patient was evaluated as complete response, 6 as partial response, 8 as stable disease, and 6 as progressive disease. One patient was not evaluable because therapy had to be discontinued as a result of jaundice. The median survival time was 15.3 months (95% CI: 4.4-26.2 months). The 1- and 2-year survival rates were 54.9 and 36.6%, respectively. The overall response rate was 31.8% and the disease control rate was 68.2%. Grade 3 neutropenia (18.2%), leukopenia (9.1%), anemia (9.1%), and thrombocytopenia (18.2%) were observed. Grade 4 toxicities were not observed.

CONCLUSION

Combination therapy with S-1 and PEG-IFN is effective and feasible, and is therefore a promising regimen for advanced HCC.

摘要

目的

目前对于伴有血管侵犯或肝外转移的晚期肝细胞癌（HCC）患者尚无有效的治疗方法。我们评估了S-1与聚乙二醇干扰素（PEG-IFN）-α联合治疗晚期HCC的疗效和安全性。

方法

共有22例患者接受了S-1与PEG-IFN的联合治疗。联合治疗的一个周期包括口服S-1（80mg/m²）和皮下注射PEG-IFN（PEG-IFN-α-2a 90μg每周或PEG-IFN-α-2b 50μg每周），持续4周，间隔1至2周。

结果

1例患者评估为完全缓解，6例为部分缓解，8例为疾病稳定，6例为疾病进展。1例患者因黄疸不得不停止治疗，无法进行评估。中位生存时间为15.3个月（95%CI：4.4 - 26.2个月）。1年和2年生存率分别为54.9%和36.6%。总缓解率为31.8%，疾病控制率为68.2%。观察到3级中性粒细胞减少（18.2%）、白细胞减少（9.1%）、贫血（9.1%）和血小板减少（18.2%）。未观察到4级毒性反应。